Vyne Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VYNE Nasdaq 8731 https://vynetherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vyne Therapeutics Inc

VYNE Therapeutics to Attend BIO International Convention - May 18th, 2023 12:00 pm
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - May 11th, 2023 8:01 pm
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions - May 1st, 2023 12:00 pm
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis - Apr 19th, 2023 12:00 pm
VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201 - Mar 30th, 2023 11:45 am
VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference - Mar 22nd, 2023 12:00 pm
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update - Mar 9th, 2023 9:01 pm
VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule - Feb 28th, 2023 9:00 pm
VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference - Feb 22nd, 2023 1:00 pm
VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201 - Feb 15th, 2023 1:00 pm
VYNE Therapeutics Announces Reverse Stock Split - Feb 10th, 2023 1:00 pm
VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201 - Jan 9th, 2023 9:01 pm
VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event - Dec 12th, 2022 1:00 pm
VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform - Dec 7th, 2022 1:00 pm
VYNE Therapeutics to Participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference - Dec 2nd, 2022 1:00 pm
VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference - Nov 18th, 2022 1:00 pm
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo - Nov 17th, 2022 1:00 pm
VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 10th, 2022 9:01 pm
VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Sep 6th, 2022 12:00 pm
VYNE Therapeutics Reports Second Quarter 2022 Financial Results - Aug 12th, 2022 12:00 pm